AyuVis Research, Inc. is pioneering a new generation of immunotherapies that modulate the innate immune system to control hyperinflammation and eliminate microbial pathogens. These compounds have been evaluated in a spectrum of preclinical disease models, using a variety of formulations and delivery routes, with positive therapeutic results. During this evaluation process, AyuVis demonstrated that altering the chemical structure of its compounds will result in enhanced anti-inflammatory activity, enhanced anti-microbial activity, or a balanced combination of both. The anti-inflammatory properties, unlike steroids, do not suppress the immune system. The anti-microbial action is synergistic with conventional antibiotic therapies. Based on promising preclinical data, AyuVis is developing first-in-class therapies for life-threatening, orphan, respiratory diseases including Bronchopulmonary Dysplasia, a leading cause of neonatal lung injury, Pseudomonas aeruginosa Pneumonia, and Acute Respiratory Distress Syndrome. Together these indications have a market potential of over $2.5 Billion. Preclinical testing in animal models has demonstrated effective results for intravenous (IV), intranasal (IN), and intraperitoneal (IP) administration and the lead compound has an excellent PK and safety profile. AyuVis is near clinical stage with a Phase 1 Healthy Adult Volunteer Safety Study planned to begin within the next 12 months.